Tonix Pharmaceuticals Doses Participants in Phase 1 Study Evaluating TNX-601 for the Daytime Treatment of Posttraumatic Stress Disorder
Stock Information for Tonix Pharmaceuticals Holding Corp.
Loading
Please wait while we load your information from QuoteMedia.